Current guidelines for the management of dyslipidemia recommend the use of PCSK9 inhibitors in patients at high or very high risk of future cardiovascular events, in whom LDL-C targets are not achieved with maximally tolerated statins and ezetimibe, and in those who are statin intolerant. Here, PCSK9 is linked to metabolic syndrome.